Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PURETHAL Mites
- Development stage
- Phase 3
- Lead developer
- HAL Allergy
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
PURETHAL Mites is a subcutaneous house dust mite allergy vaccine developed by HAL Allergy. It is designed for the treatment of allergic rhinitis and rhinoconjunctivitis caused by house dust mites. The vaccine contains chemically modified extracts from *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*, adsorbed to aluminum hydroxide. It acts as an immunomodulator to reduce allergic reactions.
- Brand names
- PURETHAL Mites
- Other names
- House dust mite allergy vaccine
Beyond the preview
Go deeper on PURETHAL Mites.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PURETHAL Mites.